| Nov 21 |
Perspective slips after Phase 1/2 trial data for radio pharma drug
|
| Nov 21 |
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
|
| Nov 16 |
Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?
|
| Nov 15 |
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
|
| Nov 12 |
Perspective Therapeutics: Q3 Earnings Snapshot
|
| Nov 12 |
Perspective Therapeutics GAAP EPS of -$0.21 beats by $0.01, revenue of $0.37M beats by $0.22M
|
| Nov 12 |
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
Perspective Therapeutics Q3 2024 Earnings Preview
|
| Oct 31 |
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
|
